Division of Alexion Pharmaceuticals Inc.
Latest From Syntimmune Inc.
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases, involving bivalent antibody-mimetic scaffolds and novel peptides.
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- North America
- Parent & Subsidiaries
- Alexion Pharmaceuticals Inc.
- Senior Management
Jean-Paul Kress, MD, Pres. & CEO
Laurence Blumberg, MD, COO
Mario Saltarelli, MD, PhD, CMO
John McBride, CMO
- Contact Info
Phone: (617) 206-4220
116 Huntington Ave.
Boston, MA 02116
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.